Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD IL2 + Ipilimumab + Nivolumab in Advanced Melanoma
NCT04562129Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Sep 2020
- Primary completion
- Jul 2026
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin, ipilimumab and nivolumab in melanoma, sponsored by Moffitt Cancer Center. Primary endpoint: Objective Response Rate at 9 months. Started Sep 2020; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04562129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04562129.